Chau Cheng

Chau Cheng, Ph.D., M.B.A. is Vice President of Investor Relations at Immunovant. He has more than 18 years of experience leading the investor relations function of small- and mid-cap biotech companies.

Chau most recently served as Vice President, Investor Relations and Corporate Communications at CytomX Therapeutics, where he worked closely with the C-suite on crafting corporate messaging and articulating competitive positioning in front of the investment community. Prior to CytomX, Chau spent more than 16 years at Immunomedics during which the company transformed from a research and development-oriented organization to a fully-integrated biopharmaceutical enterprise.

Chau earned a B.Sc. (First Class Honors) in Chemistry from University of Bradford, the United Kingdom, a Ph.D. in Organic Chemistry from The Open University, the United Kingdom, and a M.B.A. in Finance and International Business from Stern School of Business, New York University.